Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10797991 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8900702 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL708773 | 0.96 | LMNA (0.39) | LMNATHRB | |
| SCHEMBL9580829 | 0.85 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL379028 | 0.84 | LMNA (0.33) | LMNA | |
| SCHEMBL8469138 | 0.83 | ALDH1A1 (0.30) | LMNA | |
| SCHEMBL11693903 | 0.80 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8675830 | 0.80 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8749128 | 0.80 | — | — | |
| SCHEMBL6846353 | 0.80 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106498-A1 | PERFUSION FLUID, METHODS OF PRODUCING PERFUSION FLUID, AND ITS USES | NanoSanguis S.A. (PL) | 2026-05-21 | — | — | WO | claimed |
| EP-4744486-A1 | PERFUSION FLUID, METHODS OF PRODUCING PERFUSION FLUID, AND ITS USES. | NanoSanguis S.A. (PL) | 2026-05-20 | — | — | EP | claimed |
| EP-4744487-A1 | FLUID, METHODS OF PRODUCING FLUID, AND ITS USES | NanoSanguis S.A. (PL) | 2026-05-20 | — | — | EP | claimed |
| EP-4704937-A1 | DEVICE FOR THE ENTERAL ABSORPTION OF CO2, AND CORRESPONDING SET | O11 biomedical GmbH (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20250381232-A1 | BONE DERIVED FIBERS AND OXYGENATED WOUND TREATMENTS | TETROUS INC (US) | 2025-12-18 | — | — | US | claimed |
| US-12419916-B2 | Bone derived fibers and oxygenated wound treatments | TETROUS, INC. (US) | 2025-09-23 | — | — | US | claimed |
| EP-4580680-A1 | LECITHIN-MODIFIED NANOSCALE OXYGEN CARRIERS (LENOX) | Universität Duisburg-Essen (DE) | 2025-07-09 | — | — | EP | claimed |
| WO-2025093759-A1 | DEVICE FOR THE ENTERAL ABSORPTION OF CO2, AND CORRESPONDING SET | O11-BIOMEDICAL GMBH (DE) | 2025-05-08 | — | — | WO | claimed |
| EP-4520312-A2 | THERAPEUTIC GAS INFUSED COSMETIC AND METHODS OF INFUSION | Tetrous, Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| CN-119498276-A | Novel organ cryopreservation liquid based on PVP (polyvinyl pyrrolidone) fluorocarbon emulsion | 北京医院 | 2025-02-25 | — | — | CN | claimed |
| US-5614170-A | CONTRAST AGENTS OF DIETHYLENETRIAMINEPENTAACETIC ACID CHELATE COMPOUNDS | HEMAGEN/PFC (US) | 1997-03-25 | — | — | US | claimed |
| WO-1996041647-A1 | SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS | BARNES-JEWISH HOSPITAL D/B/A (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996035411-A1 | HOMOGENEOUS WATER-IN-PERFLUOROCHEMICAL STABLE LIQUID DISPERSION FOR ADMINISTRATION OF A DRUG TO THE LUNG OF AN ANIMAL | HEMAGEN/PFC (US) | 1996-11-14 | — | — | WO | claimed |
| US-5571498-A | Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI). | HEMAGEN/PFC (US) | 1996-11-05 | — | — | US | claimed |
| WO-1996016679-A1 | PARAMAGNETIC COMPLEXES OF N-ALKYL-N-HYDROXYLAMIDES OF ORGANIC ACIDS AND EMULSIONS CONTAINING SAME FOR MAGNETIC RESONANCE IMAGING (MRI) | HEMAGEN/PFC (US) | 1996-06-06 | — | — | WO | claimed |
| WO-1996013268-A2 | USE OF A CORTICOSTEROID TO REDUCE THE ADVERSE EFFECTS OF A PERFLUOROCHEMICAL EMULSION | HEMAGEN/PFC (US) | 1996-05-09 | — | — | WO | claimed |
| WO-1995033494-A1 | EMULSIONS OF PARAMAGNETIC CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING (MRI), CONTAINING AN ORGANIC CHELATOR HAVING AN UNSATURATED ALIPHATIC GROUP | HEMAGEN/PFC (US) | 1995-12-14 | — | — | WO | claimed |
| EP-0642364-A1 | METHOD AND APPARATUS FOR EXTRACORPOREAL SEPARATION OF FLUOROCHEMICALS FROM WHOLE BLOOD OF A PATIENT. | HEMAGEN PFC (US) | 1995-03-15 | — | — | EP | claimed |
| US-5295953-A | Method and apparatus for extracorporeal separation of fluorochemicals from whole blood of a patient | HEMAGEN/PFC (US) | 1994-03-22 | — | — | US | claimed |
| WO-1993024158-A1 | METHOD AND APPARATUS FOR EXTRACORPOREAL SEPARATION OF FLUOROCHEMICALS FROM WHOLE BLOOD OF A PATIENT | HEMAGEN/PFC (US) | 1993-12-09 | — | — | WO | claimed |